| |
Fig. 6. Effects of Mst1/2 MO injection on hematopoietic and endothelial progenitors. (A-H) At the early stage, no differences in the expression of hematopoietic and endothelial progenitor markers, Scl, Runx1, Lmo2, and Gata2, were observed between standard control MO (Std. MO, 5 ng)- and Mst1/2 MO (Mst1t+2s MO, 2.5/2.5 ng)-injected embryos. (I-N) In the Mst1/2 morphant, expressions of early myeloid progenitor marker, C/EBP_ and Spib were maintained in aVBI, but reduction of migrating differentiated myeloid cells was observed. Arrow indicate migrating myeloid cells from aVBI. (O-V) At the later stage, following the differentiation of hematopoietic cells, Scl, Runx1, Lmo2, and Gata2 expression gradually decreased in the VBI of standard control MO-injected embryos, whereas these markers were continuously expressed at similar levels in the Mst1/2 knockdown embryo. (W,X) The pre-erythroblast marker, Gata1, was markedly decreased by Mst1/2 knockdown. (Y-b) The expression patterns of the endothelial progenitor marker, Fli1 and Etv2, were disrupted by depletion of Mst1/2. Sample numbers are indicated in the upper right of each panel, and developmental stage is indicated in the lower left. Assessed marker is indicated in the lower right of each panel. |
